Navigation Links
Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome

Torrance-based firm will introduce NutreStore(TM) in spring 2008

TORRANCE, Calif., Dec. 19 /PRNewswire/ -- Emmaus Medical, Inc., a Torrance, California based pharmaceutical company, announced today that it has entered into an exclusive sublicense agreement with Cato BioVentures of Research Triangle Park, North Carolina for the patent protected drug NutreStore(TM) brand L-Glutamine. Under this agreement, Emmaus will commercialize NutreStore(TM), which is approved by the FDA for use in combination with human growth hormone as a treatment for short bowel syndrome (SBS). Emmaus will be introducing NutreStore(TM) in the spring of 2008 and projects that its sales will greatly contribute to its short and long term financial performance of the company.

SBS is a serious and life threatening condition afflicting around 20,000 Americans who have lost large portions of their small intestine. This leads to a malnourished condition requiring total parenteral nutrition (TPN) through intravenous feeding.

NutreStore(TM) in conjunction with human growth hormone and an appropriate diet is the first new treatment since the development of TPN for patients with short bowel syndrome. Clinical studies of this combination therapy administered to SBS patients dependent upon TPN for nutritional support showed a significant reduction in the required weekly volume, caloric content and frequency of TPN administration compared to patients treated with human growth hormone alone. "This combination therapy offers patients a unique opportunity to improve intestinal absorption of food, which leads to a much better quality of life for SBS patients," said Douglas Wilmore, M.D., a board member of Emmaus. Dr. Wilmore is an Emeritus Frank Sawyer Professor of Surgery at Harvard Medical School, the inventor of this SBS treatment, and Editor-in-Chief of the Medscape General Surgery section of Medscape Today, at

Currently, patients who require L-Glutamine must purchase non-pharmaceutical grade L-Glutamine on their own without insurance coverage. With a prescription, NutreStore(TM) will be covered by insurance, thus lifting a large financial burden from patients who wish to optimize their SBS treatment with an FDA approved pharmaceutical product.

"Cato BioVentures is excited to partner with Emmaus Medical for the marketing of NutreStore(TM) and looks forward to a long and successful relationship with the company," said Joel Eisner, Ph.D., Associate Principal of Cato BioVentures.

About Emmaus Medical, Inc.

Emmaus Medical, Inc., led by Yutaka Niihara, M.D., M.P.H., CEO, and Daniel R. Kimbell, Esq., COO, is a private company founded to develop new treatments for sickle cell disease and other orphan diseases such as SBS. Emmaus works closely with the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) and is currently conducting multi-center, double blind, placebo controlled, clinical trials to determine the safety and efficacy of L-Glutamine for sickle cell disease. Emmaus Medical is the recipient of an FDA orphan drug designation and fast track designation for the sickle cell project. For more information, please visit our website

About Cato BioVentures

Cato BioVentures is the venture capital affiliate of Cato Research Ltd. For nearly 20 years, Cato BioVentures has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic CRO service agreements with Cato Research, Cato BioVentures invests its in-kind CRO Service Capital in innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has offices in Boston's Bay Colony, Research Triangle Park and Silicon Valley. For more information, please visit our website


Henry Macan, M.D., Senior Manager

Emmaus Medical, Inc.

3870 Del Amo Boulevard, Unit 507

Torrance, CA 90503-7701

Tel. 310.214.0065


Joel Eisner, Ph.D., Associate Principal

Cato BioVentures

4364 South Alston Avenue

Durham, NC 27713

Tel. 919-361-2286


SOURCE Emmaus Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
11. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers
Post Your Comments:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
Breaking Medicine Technology: